Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus CHOP for newly diagnosed Richter's syndrome
2009-016459-23Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in Richter's syndrome (RS) and diffuse large B-cell lymphoma (DLBCL), sponsored by University of Oxford. Primary endpoint: Overall response rate at week 72. Started Oct 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-016459-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016459-23.